Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Retrospective Radiomics-Based Subtyping Study to Guide Post-Downstaging Treatment Selection in Patients With Unresectable Hepatocellular Carcinoma Following TACE Plus Lenvatinib and Anti PD-1

NCT07581769 is registered in ClinicalTrials.gov with First Affiliated Hospital, Sun Yat-Sen University as lead sponsor.

NCT NCT07581769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07581769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Retrospective Radiomics-Based Subtyping Study to Guide Post-Downstaging Treatment Selection in Patients With Unresectable Hepatocellular Carcinoma Following TACE Plus Lenvatinib and Anti PD-1
Lead sponsor
First Affiliated Hospital, Sun Yat-Sen University
Phase
Observational
Overall status
Active, not recruiting
Start date
January 1, 2018
Completion date
December 31, 2026
Enrollment
500 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

downstaging, hepatocellular carcinoma (hcc), lenvatinib, liver resection, pd1 antibody, transarterial chemoembolization